Yes, CNVs can be targeted for cancer therapy. Targeted therapies have been developed to specifically inhibit the function of proteins overexpressed due to CNV. For example, inhibitors targeting the amplified gene products of EGFR in lung cancer or HER2 in breast cancer have shown significant clinical efficacy. Ongoing research aims to identify novel CNV targets and develop corresponding therapeutic strategies.
